Latest news with #TLR
Yahoo
13-06-2025
- Politics
- Yahoo
Top Texas donor slams Speaker Burrows, House members after legislative setbacks
The Houston Chronicle is part of an initiative with ProPublica and The Texas Tribune to report on how power is wielded in Texas. Leaders for Texans for Lawsuit Reform, the biggest donor in Texas politics, say they have a simple strategy when trying to persuade state lawmakers: 'We never make enemies,' President Lee Parsley said in late April. 'We only make friends.' But now that the Texas legislative session has concluded without lawmakers passing any of the group's three high priority bills, TLR is taking a decidedly different tact. In a blistering letter to members, Parsley called out by name the lawmakers he said stifled TLR's agenda and all but promised to take them on in primary campaigns next March. He laid much of the blame on House Speaker Dustin Burrows' shoulders. [Houston megadonor Dick Weekley and his group Texans for Lawsuit Reform are losing in the Legislature after 30 years of wins] The group's political action committee 'must redouble our efforts to elect strong, ethical, legislators who value a civil justice system that has integrity,' Parsley wrote in his letter to the group's members last week. Its signature priority, Senate Bill 30 – an effort to rein in medical costs in personal injury lawsuits – died after the House and Senate passed vastly different versions of the bill and could not reconcile the differences. 'I think it's fair to say we may look at backing some primary challengers,' Parsley said. 'We'll take a good look at what happened toward the end of session and decide how to engage politically, but the people who did not support TLR's bill fully are certainly people who will be a focus for us.' The legislative strikeout on these civil justice bills marks a low point for TLR, which won massive rewrites of the Texas civil justice code in the 1990s and early 2000s, spending millions to elect like-minded lawmakers and lobby them to pass the legislation. At its height, the group – led by Houston's most prolific political donor, the homebuilder Richard Weekley – was largely seen as synonymous with the Texas Republican Party, positioning itself as the political voice of the state's business community. The group's political action committee remains the top political spender in the state, spending $21.2 million on legislative races in 2024. The tone of its letter suggests the group could be on a warpath in the March primary elections. Instead of protecting incumbents, TLR could begin targeting members who bucked the group's wishes. 'It did feel a little strange because TLR has basically gotten everything they wanted for a long time now, and the one time it seems like they didn't, it feels like they're throwing a tantrum about it,' said Andrew Cates, a Democratic legislative lawyer and former lobbyist in Austin. 'Everybody else would have been licking their wounds and hanging back and trying to make nice.' TLR's letter alleged Burrows placed skeptical lawmakers on the key committees charged with shepherding SB30. It also called out state Rep. Marc LaHood, R-San Antonio, the main holdout on the House committee that forced significant revisions to the legislation; and state Rep. Mitch Little, R-Lewisville, who helped win passage of an amendment that TLR said made the bill 'ineffective.' It named more than a dozen other Republican members as well, several of whom defeated TLR-backed candidates in last year's GOP primaries. Cates said the group's criticism of Burrows was notable, since lobbying groups rarely take those kinds of disputes public. Burrows has been endorsed by President Donald Trump for another term, and speakers have broad power to block legislation in future sessions. 'The political capital is going to be really wasted if you come at him and miss,' Cates said. When asked if TLR would support a primary candidate against the speaker, Parsley paused and said, 'Not ready to comment on that.' Other lawmakers responded to the accusations with barbs of their own. 'Simply put, TLR lies,' LaHood wrote in a response on X. Little said in an interview, 'Obviously, they were upset with the outcome and looking for people to blame or attack, but I'll just say on my part, I forgive them and I'm not offended by any of it. I understand that their policy agenda failed.' Burrows' office did not respond to requests for comment. But Little said TLR's claim that Burrows led the effort to tank the legislation is 'not true in any way.' This year, TLR pushed three bills: SB30, which advanced the farthest but was significantly watered down as the session wore on; SB39, which dealt with civil liability for trucking companies; and SB779, which would crack down on 'public nuisance' lawsuits that cities and counties sometimes file against companies on behalf of the public. SB30 started off ambitious. The original draft, passed quickly by the Senate, would have required appellate courts to reduce or review large jury verdicts, capped medical costs by tying them to what Medicare pays out for services and combined several different lines of action for plaintiffs into one newly defined category of 'mental anguish.' One by one, each of those measures were cut. Still, even the watered-down version of SB30 did not have enough votes to get out of the House Committee on Judiciary & Civil Jurisprudence, said state Rep. Joe Moody, one of five Democrats on the 11-member committee. The bill looked like it would languish in the committee without a vote. In its letter, TLR blamed Burrows for the committee rosters, saying his selections made it more difficult to pass the legislation. But Moody said it was Burrows who revived the bill, wanting to ensure that at least some portion of TLR's agenda made it to the House floor. On May 20, Burrows urged the committee members to renew discussions on SB30 and come up with a version that they could agree on, Moody recalled. What resulted was a 12-hour negotiation that Little was also asked to join, though he was not a member of the committee. The outcome of that meeting was a stripped-down bill that mainly would do one thing: require judges to automatically admit certain benchmarks to establish reasonable medical charges. The bill passed through the committee, with Moody and LaHood in support. TLR's letter also blasted LaHood's performance on the committee, saying it was concerned from the start that he 'was not philosophically aligned with the business community, and we were right.' It accused LaHood of fleeing the committee meeting to avoid having to vote on TLR's other two bills, meaning 'both bills would die in committee.' 'I did not 'flee' the JCJN committee room after SB30 was voted out,' LaHood wrote in response, saying his opposition to those bills was clear. 'As the Chairman knew, I left to lay out a bill in another committee. Afterward, I returned, and we continued to vote out more bills… I do not run from a fight or a tough vote.' LaHood said he was 'appalled by the breadth of what TLR was attempting to codify into law,' and he said 'TLR's ham-fisted attempt to shirk responsibility for their poorly drafted, poorly conceived bills' impugned his character along with Burrows, Little and the entire House chamber. State Rep. Jeff Leach, R-Allen, who chaired the committee, put out a statement clarifying the committee meeting. He said he knew LaHood's position, which meant the bills did not have the votes to pass, and decided to shelf the bills. 'That was my decision and my decision alone,' Leach said. Committee records back up that account. They show that LaHood temporarily left the meeting and that, in his absence, two other bills failed because they did not get a majority vote, but after LaHood returned, Leach called them up for a vote again – and both passed. The other lawmaker to draw TLR's ire was Little. After the revised version of SB30 advanced to the House floor, TLR suffered one final defeat. Moody and Little were concerned about making evidence automatically admissible, since that requirement is rare in Texas law. On the floor, they introduced an amendment that would allow judges to exercise some discretion about whether to admit the evidence. For example, they would be able to consider whether the evidence was relevant to their specific case. TLR described it as a 'gutting amendment.' The group accused Little of reversing course after negotiating the bill that passed the committee. The bill 'would be killed by' Little, Parsley wrote. Moody and Little both said that was not true; they had made it clear the issue was not totally resolved during those negotiations, both lawmakers said. Little said he supported the change out of 'loyalty to the law and the application of the rules of evidence.' The House passed the amendment on a razor thin margin, 72-70, gutting the bill in TLR's eyes. Little said the vote showed that the House probably did not have the votes to pass the bill without the amendment. 'There was still one chance to save the bill,' Parsley wrote, referring to the conference committee charged with reconciling differences in the House and Senate versions. But Burrows put Little on the committee as the swing vote, ensuring the amendment would remain, he said. The House lawmakers refused to cut the amendment, and the bill died. Two days after lawmakers adjourned, TLR sent out its strongly worded letter. If TLR decides to go after the 17 GOP lawmakers who supported the amendment, it could open a new rift among House Republicans. That cohort is coming off a grueling 2024 primary season fought over issues like Gov. Greg Abbott's school voucher plan and Attorney General Ken Paxton's impeachment. TLR invested $14 million in the primary cycle last year, but it was on the losing side of many of those campaigns, spending roughly $6 million to back incumbents in races they lost. Among the large freshman bloc that swept into office in those campaigns, 10 cast votes against TLR by backing Moody's amendment. Those candidates had already defeated TLR's money in one primary and may have been less beholden to them than those in the past. LaHood and Little were among them. TLR gave $320,000 to Little's opponent, Kronda Thimesch, and $99,500 to former state Rep. Steve Allison, who lost to LaHood. The political action committee, however, gave money to LaHood for his general election campaign. The group's single biggest beneficiary during the primary campaign was Jeff Bauknight, doling out nearly $1 million to back his campaign for a house seat in Victoria. He lost to state Rep. AJ Louderback, R-Victoria – who voted for Moody's amendment. State Reps. Andy Hopper, Shelley Luther, Brent Money, Mike Olcott, Katrina Pierson and Wes Virdell all were namechecked in TLR's letter of what it called a 'bad session.' Each beat TLR-backed candidates in their primary campaigns last year. Others listed by TLR included veteran members who TLR has supported in the past. TLR's losses last primary season may portend trouble in trying to target members who opposed them this year. But the group still has a massive war chest of $26.8 million, according to campaign finance records. It usually reports raising about $6 million after a legislative session wraps up. It will have to disclose how much more money it has raised this year in July. 'We understand the realities of Texas politics. I think that what we're doing is the right thing.' Parsley said. 'If the litigation environment remains the same for a long period of time, they will all realize that we were right about this all along, and they will wish they'd paid more attention to us.' Big news: 20 more speakers join the TribFest lineup! New additions include Margaret Spellings, former U.S. secretary of education and CEO of the Bipartisan Policy Center; Michael Curry, former presiding bishop and primate of The Episcopal Church; Beto O'Rourke, former U.S. Representative, D-El Paso; Joe Lonsdale, entrepreneur, founder and managing partner at 8VC; and Katie Phang, journalist and trial lawyer. Get tickets. TribFest 2025 is presented by JPMorganChase.
Yahoo
11-06-2025
- Entertainment
- Yahoo
Baseball Legend Tony La Russa partners with The PenFed Foundation for Military Heroes to Celebrate St. Louis Cardinals' Historic Championships
July 16 celebration in St. Louis honors iconic baseball players and veterans Wednesday, July 16, 2025 @ 6:45 PM Stifel Theatre 1400 Market Street St. Louis, MO 314-499-7600 TYSONS, Va., June 11, 2025 /PRNewswire/ -- The PenFed Foundation for Military Heroes is honored to partner with baseball icon Tony La Russa, for an unprecedented celebration of the St. Louis Cardinals' 2006 and 2011 World Series championships. La Russa also led the Cardinals to three National League pennants during his tenure with the team. The presentation will feature highlight videos from 2000 to 2011, with former players describing key game moments and up close and personal behind the scenes experiences. It is certain to be filled with magical moments! October appearances in the '60s and '80s will also be recognized. Players committed to attending include Rick Ankiel, Will Clark, David Eckstein, Jim Edmonds, David Freese, Al Hrabosky, Jason Isringhausen, Mike Matheny, Matt Morris, Reggie Sanders and Woody Williams. Sports broadcaster Joe Buck will also be in attendance and other players will be announced. The evening will also include special tributes to: Darryl Kile, who tied for first for the best teammate ever, and the legendary Jack Buck. Losing them in 2002 inspired the team into October. Walt Jocketty, the architect of the culture and talent that began the winning era. Tom Satterly, a multi decorated Delta Force Sgt. Major who for 20 plus years fought for our country, and now with his wife Jen, cares for returning warriors and their families. The audience will have fun with comedian Tom Cotter, runner-up in America's Got Talent Year 7. Ironically, he lost to Olathe Dogs. The program supports the missions of these nonprofit organizations: La Russa Rescue Champions and its Partnership with The PenFed Foundation for Military Heroes empowering veterans as they transition from service to success in their civilian lives, including connecting them to life-changing service dogs. All Secure Foundation healing special operators and families from traumas of war. Cardinals Care improving the lives of kids. Center for Animal Rescue & Enrichment; Five Acres Animal Shelter; Home 2 Home Canine Orphanage; Open Door Animal Sanctuary; and St Louis Pet Rescue – local no kill rescue groups. The goal is to present a historic night to remember for our fans and members of the Cardinals while also contributing to special causes. Tickets are available at four levels and priced so that as many interested fans as possible can attend. Fortunately, the Stifel Theatre has great seats throughout the building. Level I - Central Div. Champs - $40 Level II - Div, Series Champs - $65 Level III - League Champs Series - $150 includes a post-event Q&A with TLR Level IV- World Series Champs - $250 includes a pre event Q&A with TLR and a post-event reception with the players and Tom and Jen Satterly. All the show participants and volunteer supporters are donating their efforts. To help defray expenses several sponsorships have been created. Each sponsorship provides an appropriate number of Level IV World Series Champs tickets! The event sponsor is ApexNetwork Physical Therapy. There are currently several sponsorships available at the $5,000 level including show's first half, show's second half, military segment and veterans and first responder guests. Additionally, a post-event reception sponsorship is available for $4,000 and two pre and post-show Q&As at $2,500 each. There is also a unique travel sponsorship that covers the total air fares for participants at $1,000 per responder travel team members will each receive two Level IV World Series Champs tickets. "We hope you, family and friends will join us and bring your legendary enthusiastic support!" said LaRussa. Tickets are available through Also, directly at the Stifel Theatre Box Office. Open at 12:00 on days the theatre hosts an event! For further information, leave a message at 925-395-1505. About PenFed Foundation for Military HeroesFounded in 2001, The PenFed Foundation for Military Heroes is a national nonprofit organization that supports veterans in their transition from service to success in the civilian world. Affiliated with PenFed Credit Union, the Foundation has provided more than $55 million in financial support to veterans, active-duty service members and military families. PenFed Credit Union covers most of the salaries and administrative costs of The PenFed Foundation for Military Heroes, so more of your donation goes right to our programs. To learn more, please visit View original content to download multimedia: SOURCE PenFed Foundation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-06-2025
- Business
- Yahoo
Personal injury, trucking lawsuit bills die
AUSTIN (KXAN) — A pair of bills backed by Texans for Lawsuit Reform, aimed at reducing large jury verdicts in personal injury and trucking accident cases, died this legislative session. Senate Bill 30 — filed with the goal of 'curbing nuclear verdicts' — and Senate Bill 39 were two of Lt. Gov. Dan Patrick's priority bills for this legislative session. Under SB 30, a jury would have heard if an attorney referred their client — and others over the past two years — to a specific doctor. That provider would have had to submit an affidavit that treatment was reasonable and disclose any agreement guaranteeing they are reimbursed for treatment costs in a settlement. Medical expenses would be reimbursed based off rates paid by Medicare and workers' compensation insurance. Critics said the bill would have required victims to introduce evidence unrelated to their case or care and could have unintentionally made it harder for sexual assault survivors to hold abusers accountable. Deadly truck crash foreshadows fight between business, safety at Capitol The bill was amended in the House, but those changes were not approved by the Senate. 'Today, a kind of fraud is occurring in courtrooms across Texas, as personal injury attorneys and collaborative doctors manufacture medical bills and present them to jurors as if they are legitimate,' said TLR President Lee Parsley. 'This unethical activity is increasing insurance premiums for every business operating in Texas. Ultimately, the increased cost of doing business is being paid by every Texan. We are disappointed the legislature did not enact laws necessary to stop this well-documented, barely hidden abuse of our legal system.' Another bill, SB 39, took aim at commercial vehicle lawsuits. Patrick said the bill was about 'protecting Texas trucking.' Critics said it would have presented new legal hurdles to make it harder for injured victims to introduce evidence about a company's alleged negligence. Debate about the bill occurred at the same time a truck driver was arrested for causing an 18-vehicle pileup on Interstate 35 in north Austin, killing five people and injuring 11 others, according to Austin Police. Last year, a KXAN investigation first revealed the intention of TLR and a coalition of businesses to back bills this legislative session aimed at lawsuit reforms as a way to stop what it called 'nuclear verdicts' and bring down rising insurance rates. 'For four decades, Texans' legal rights have been under constant assault by corporate lobbyists at the Texas Capitol. This session, lawmakers said 'no more,' rejecting SB 30 and SB 39,' countered consumer advocate Ware Wendell, with the nonpartisan group Texas Watch. 'The bills' backers sought to undermine the Rules of Evidence, putting their thumbs on the scales of justice. Juries deserve to hear the whole truth upfront, and judges deserve to rule on these matters. Our independent judiciary was protected when these bills died.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
27-05-2025
- Business
- Yahoo
House takes up injury lawsuit reform bill
AUSTIN (KXAN) — An injury lawsuit reform bill critics say will make it harder for victims to receive justice inched closer to becoming law when the Texas House voted to pass it 94-52 late Monday evening. Under Senate Bill 30, a jury would hear if an attorney referred their client — and others over the past two years — to a doctor. That provider must submit an affidavit that treatment was reasonable and medical expenses should be based off rates paid by Medicare and workers' compensation insurance. The House debated and added multiple amendments to the bill, which was backed by Texans for Lawsuit Reform. This legislative session, TLR has pushed for bills related to trucking accidents and personal injury and wrongful death lawsuits aimed at lowering insurance costs and stopping what it calls 'nuclear verdicts.' 'Even though the proponents of these bills talk about lowering insurance costs, the bills never mention the word 'insurance.' The bills don't do anything to insurance companies,' said Ware Wendell with the consumer and patient advocacy group Texas Watch. 'They just infringe upon our rights.' Lt. Gov. Dan Patrick had listed SB 30 as a priority bill this session along with the goal of 'curbing' large jury verdicts. Despite victim pushback, Senate passes trucking lawsuit bill TLR said the bill targets what it believes are often 'inflated' medical costs that are presented at trial, which attorneys and medical providers dispute. 'It will limit the ability of some lawyers and collaborating health care providers to cheat,' TLR General Counsel Lee Parsley told lawmakers in March. Parsley said the bill does not cap damages or 'prevent an injured person from recovering the full measure of compensatory and non-economic damages.' The Lone Star Economic Alliance, which represents a coalition of Texas businesses, said the bill addresses 'the rising wave of abusive lawsuits' and reduces pressure to settle 'meritless claims.' Last year, a KXAN investigation first revealed LSEA's intention to push for more lawsuit reforms. 'Texas is known as the best state for business,' LSEA previously said in a statement. 'Unfortunately, our legal system has become a liability in an otherwise strong pro-business climate, and if we fail to fix it, we threaten the competitive advantages that generations of Texans have worked hard to build.' Wendell, however, said the bill creates unnecessary 'burdens for patients' when it comes to how medical costs and damages can be presented to a jury. 'It's really a giveaway to the insurance companies, who aren't going to have to pay full medical costs under the bill,' said Wendell. Deadly truck crashes foreshadowed fight between business, safety at Capitol The Senate version of the bill required corroborating medical evidence, or 'prior consistent statements,' for a jury to consider pain and suffering damages. Survivors of childhood sexual assault pushed back on that in recent months, worried it would make it harder to hold abusers accountable in a civil cases. Among those who spoke out was a 20-year-old who told a Senate panel he was repeatedly raped and groomed at 11-years-old by his adopted step-father, who is serving time in prison. 'This abuse was not just sexual but also physical, verbal and emotional and the effects will continue for the rest of my life,' the survivor told lawmakers. 'When I think back on what happened to me, I can only describe it as a personal hell. How do you put a cap on seven years of hell?' The bill will get another procedural vote on Tuesday before heading back to the Senate for final approval. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Associated Press
23-05-2025
- Business
- Associated Press
ENHERTU® (trastuzumab deruxtecan) Receives Time-Limited Reimbursement Recommendation from Canada's Drug Agency for Gastric Cancer
MISSISSAUGA, ON, May 23, 2025 /CNW/ - AstraZeneca (AZ) and Daiichi Sankyo (DS) are pleased to announce that Canada's Drug Agency (CDA, formerly CADTH) has issued a Time-Limited Reimbursement (TLR) recommendation – the first in gastric cancer – for ENHERTU® (trastuzumab deruxtecan) based on the unmet need of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Additionally, the pan-Canadian Pharmaceutical Alliance (pCPA), AstraZeneca, and Daiichi Sankyo have recently signed a Letter of Intent (LOI) through the recently introduced Temporary Access Process (pTAP). This step, alongside the CDA TLR processes, paves the way for jurisdictional reimbursement. 'As early participants in these innovative drug reimbursement processes, AstraZeneca and Daiichi Sankyo are pleased to accelerate access to innovative treatments for Canadian patients, particularly in areas of great unmet need, such as HER2+ gastric cancer,' says Gaby Bourbara, President, AstraZeneca Canada. 'The TLR/pTAP process is intended for a subset of medicines assessed with a very specific set of criteria, and we look forward to continuing to work with our partners within the drug reimbursement ecosystem to unlock additional mechanisms for accelerating access to more medicines in the future.' It is estimated that these processes will make ENHERTU available to gastric cancer patients close to two years faster than traditional reimbursement pathways which would have required the completion and review of the Phase III DESTINY-Gastric04 study. 'Daiichi Sankyo and our partners at AstraZeneca are committed to ongoing collaboration with the HTA bodies to identify and leverage new ways to make medicines accessible to patients across the country as fast as possible following Health Canada approval,' says Fatih Yedikardeş, Country Manager, Daiichi Sankyo Canada. For medications that show early promise and have been given conditional regulatory approval, the TLR and pTAP processes represent a path for accelerated access while ongoing confirmatory trials are in progress.1,2 Health Canada granted a Notice of Compliance with conditions (NOC/c) for ENHERTU (trastuzumab deruxtecan) on January 17, 2025, for the treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.3 The conditional approval was authorized based on results from DESTINY-Gastric024 and DESTINY-Gastric015 Phase II trials. The confirmatory Phase III trial, DESTINY-Gastric046 is currently underway and is a global, randomized, open-label, trial evaluating the efficacy and safety of trastuzumab deruxtecan (6.4 mg/kg) versus ramucirumab and paclitaxel in patients with HER2- positive (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or GEJ adenocarcinoma with disease progression on or after a trastuzumab-containing regimen. About Gastric Cancer Gastric (stomach) cancer is the fifth most common cancer worldwide and the fourth leading cause of cancer mortality with a five-year survival rate of 7.5% for metastatic disease.7,8 In Canada, it is estimated that 4,200 people will be diagnosed, and 2,000 people will die from the disease this year.9 About ENHERTU ENHERTU (trastuzumab deruxtecan) is a HER2-directed antibody-drug conjugate. Designed using Daiichi Sankyo's proprietary DXd antibody drug conjugate (ADC) technology, ENHERTU consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker. About the Daiichi Sankyo and AstraZeneca Collaboration Daiichi Sankyo Company, Limited (referred to as Daiichi Sankyo) and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU in March 2019 and datopotamab deruxtecan (Dato-DXd) in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of ENHERTU and datopotamab deruxtecan. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical business whose innovative medicines are used by millions of patients worldwide. The company's core areas of scientific focus are Oncology; Cardiovascular, Renal and Metabolic (CVRM); Rare Disease; Respiratory & Immunology; and Vaccine & Immune Therapies. In Canada, the company employs more than 2,400 people and recently announced a major expansion of its research footprint in Mississauga – including the expansion of its AstraZeneca R&D Hub and the creation of a new Alexion Development Hub for Rare Diseases. AstraZeneca was recently recognized as one of Canada's Top 100 Employers, one of Canada's Most Admired Corporate Cultures, and a Greater Toronto Top Employer. AstraZeneca is committed to contributing to a more sustainable future for people, society and planet, taking important steps to help tackle some of the most pressing sustainability challenges globally – from climate and biodiversity loss, to health equity and health system resilience. AstraZeneca was one of the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative (SBTi) Corporate Net-Zero Standard. For more information, please visit the company's website at About Daiichi Sankyo Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose 'to contribute to the enrichment of quality of life around the world.' In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an 'Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.' For more information, please visit References SOURCE AstraZeneca Canada Inc.
